Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to $16.0 million.

  • Capricor Therapeutics' Cash from Investing Activities rose 69570.14% to $16.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$69.0 million, marking a year-over-year decrease of 526736.88%. This contributed to the annual value of -$116.2 million for FY2024, which is 237445.36% down from last year.
  • Latest data reveals that Capricor Therapeutics reported Cash from Investing Activities of $16.0 million as of Q3 2025, which was up 69570.14% from $14.5 million recorded in Q2 2025.
  • In the past 5 years, Capricor Therapeutics' Cash from Investing Activities registered a high of $23.9 million during Q1 2025, and its lowest value of -$123.4 million during Q4 2024.
  • For the 5-year period, Capricor Therapeutics' Cash from Investing Activities averaged around -$4.9 million, with its median value being -$322459.0 (2021).
  • Within the past 5 years, the most significant YoY rise in Capricor Therapeutics' Cash from Investing Activities was 149477.09% (2022), while the steepest drop was 1088205.14% (2022).
  • Over the past 5 years, Capricor Therapeutics' Cash from Investing Activities (Quarter) stood at -$368671.0 in 2021, then soared by 1494.77% to $5.1 million in 2022, then crashed by 214.01% to -$5.9 million in 2023, then crashed by 2004.53% to -$123.4 million in 2024, then soared by 112.93% to $16.0 million in 2025.
  • Its Cash from Investing Activities stands at $16.0 million for Q3 2025, versus $14.5 million for Q2 2025 and $23.9 million for Q1 2025.